__timestamp | Mesoblast Limited | Protagonist Therapeutics, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 55305000 | 7459000 |
Thursday, January 1, 2015 | 77593000 | 11831000 |
Friday, January 1, 2016 | 50013000 | 25705000 |
Sunday, January 1, 2017 | 58914000 | 46181000 |
Monday, January 1, 2018 | 65927000 | 59497000 |
Tuesday, January 1, 2019 | 59815000 | 65003000 |
Wednesday, January 1, 2020 | 56188000 | 74506000 |
Friday, January 1, 2021 | 53012000 | 126006000 |
Saturday, January 1, 2022 | 32815000 | 126215000 |
Sunday, January 1, 2023 | 27189000 | 120161000 |
Monday, January 1, 2024 | 25353000 |
Data in motion
In the competitive world of biotechnology, innovation is the lifeblood of success. Protagonist Therapeutics, Inc. and Mesoblast Limited are two companies that have been at the forefront of this race. Over the past decade, Protagonist Therapeutics has consistently increased its investment in research and development (R&D), with a remarkable 1,500% growth from 2014 to 2023. In contrast, Mesoblast Limited's R&D spending has seen a decline of approximately 54% over the same period.
In 2014, Mesoblast Limited led the charge with R&D expenses nearly seven times that of Protagonist Therapeutics. However, by 2023, Protagonist Therapeutics had not only closed the gap but surpassed Mesoblast, investing over four times more in innovation. This shift highlights Protagonist's commitment to advancing its research capabilities, while Mesoblast's reduced spending may indicate a strategic pivot or financial constraints.
Research and Development: Comparing Key Metrics for argenx SE and Protagonist Therapeutics, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc. Allocate Funds
Research and Development Investment: Viatris Inc. vs Protagonist Therapeutics, Inc.
Research and Development Investment: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and Protagonist Therapeutics, Inc.
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Mesoblast Limited
Research and Development Expenses Breakdown: Veracyte, Inc. vs Protagonist Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Catalyst Pharmaceuticals, Inc. and Mesoblast Limited
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE
Who Prioritizes Innovation? R&D Spending Compared for Mesoblast Limited and Evotec SE